Accuray Incorporated (ARAY) - Long-Term Debt to Capital

Corporate emblem and logo of Accuray Incorporated (ARAY)

The financial price action for Accuray Incorporated (ARAY) demonstrates the dynamics of a company whose position is strengthened by patent protection for robotics and complex equipment certification. The environmental profile is based on the safe recycling of electronics, with the metric standing at 4.13. Business stability is ensured by experienced management, which effectively expands the sales geography despite significant costs associated with developing new medical technologies.

Accuray Inc. - ARAY Long-Term Debt to Capital (period 07/04/2022 - 10/29/2026)
Original product of accuray.com

For an investor in Accuray Incorporated (ARAY), this indicator serves as a measure of financial stability during the implementation of its global expansion strategy for radiation therapy systems. By analyzing the ratio of long-term liabilities to equity, you assess the proportion of loans with maturities exceeding one year relative to net assets, which confirms the ability of the experienced management team to effectively finance expansion without a critical increase in the debt load.

Key competitors

Long-Term Debt to Equity Ratio BeiGene Ltd. (ONC)|Long-Term Debt to Capital HALO|Long-Term Debt to Capital Revolution Medicines Corp (RVMD)|Long-Term Debt to Equity Ascentage Pharma Group AAPG|CGON: Long-Term Debt to Capital Ratio|UroGen Pharma - Long-Term Debt to Capital|Bicara Therapeutics Inc (BCAX) - Long-Term Debt to Equity Ratio|PSNL: Long-Term Debt to Capital|Long-Term Liabilities to Capital Erasca Oncology (ERAS)|Long-Term Debt to Equity Delcath Systems, Inc.|YMAB: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio AURA (Aura Biosciences)|CADL (candeltx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital SLS (SELLAS Life Sciences Group)|ACTU - Long-Term Debt to Equity Ratio|CTOR: Long-Term Debt to Equity Ratio|HURA - Long-Term Debt to Capital|Protara Therapeutics, Inc. (TARA) - Long-Term Debt to Equity|Fate Therapeutics Inc - Long-Term Debt to Capital Coefficient|WHWK (Aadi Bioscience, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital TScan TCRX|Long-Term Debt to Capital CSBR|Long-Term Debt to Capital xbiotech.com (XBIT)|Long-Term Debt to Capital CVM (CEL-SCI)|OSTX - Long-Term Debt to Equity Ratio|Radiopharm Theranostics Limited - Long-Term Debt to Capital|Artiva Biotherapeutics, Inc. (ARTV) - Long-Term Debt to Equity Ratio|ANL (adlainortye.com) - Long-Term Debt to Equity Ratio|verupharma.com (VERU) - Long-Term Debt to Capital|Long-Term Debt to Equity Tempest Therapeutics, Inc.|XLO: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital RENB|Long-Term Debt to Capital muraloncology.com (MURA)|Kairos Pharma - Long-Term Debt to Equity Ratio|OnKure Therapeutics, Inc. (OKUR) - Long-Term Liabilities to Capital|GDTC: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient CRIS (Curis, Inc.)|APLM: Long-Term Debt to Capital|THAR - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Advanced Biomed Inc.|Long-Term Debt to Capital Ratio GNPX (genprex.com)|Long-Term Debt to Capital CLDI|Long-Term Debt to Equity Ratio Sunshine Biopharma Inc. SBFM|Long-Term Debt to Equity Xenetic Biosciences, Inc. XBIO|Salarius Pharma (SLRX) - Long-Term Liabilities to Capital|PPBT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient AONC (American Oncology Network)|BeiGene (BGNE) - Long-Term Debt to Equity|Long-Term Liabilities to Equity CKPT (Checkpoint Therapeutics Inc.)|Long-Term Debt to Equity Elevation Oncology, Inc.|Long-Term Liabilities to Capital iCAD Corp ICAD|Long-Term Debt to Equity Ikena Oncology, Inc. (IKNA)|NTBL (notablelabs.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital VIRX (Viracta Therapeutics, Inc.)|Long-Term Debt to Capital MorphoSys Inc MOR|NAYA: Long-Term Debt to Equity Ratio|Ascentage - Long-Term Loans to Capital Ratio